冠状动脉粥样硬化性心脏病患者Betatrophin水平及其与三酰甘油和糖化血红蛋白的相关性研究

目的  Betatrophin是一种新发现的影响糖脂代谢的因子。糖尿病和高脂血症是冠状动脉粥样硬化性心脏病（以下简称冠心病）的重要危险因素。比较冠心病患者与对照组的Betatrophin水平，并探讨其与三酰甘油（TG）和糖化血红蛋白（HbA1c）等因素的相关性。方法  测定冠心病组（107例）及与其年龄、性别、体重指数匹配的对照组（35例）的Betatrophin水平。根据HbA1c水平将冠心病组分为冠心病HbA1c正常组和冠心病HbA1c升高组。获取其他临床指标，并测定TG、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL）、高密度脂蛋白胆固醇（HDL）、肌酐（Scr）、尿酸（UA）、超敏C反应蛋白（hsCRP）、脑钠肽（BNP）和同型半胱氨酸（Hcy）水平等，分析Betatrophin与其的相关性。结果  冠心病组Betatrophin水平比对照组降低26.6%（P =0.040）。冠心病HbA1c正常组比对照组降低33.0%（P =0.001），冠心病HbA1c升高组比冠心病HbA1c正常组Betatrophin水平升高22.6%（P =0.020）。冠心病组患者Betatrophin与HbA1c呈正相关（r =0.223，P =0.021）。冠心病组男性患者比女性Betatrophin水平更低[（0.149±0.068） vs （0.181±0.078）ng/ml，P =0.028]。结论  Betatrophin可能是与冠心病患者糖脂代谢调节相关的一个新因子。

Betatrophin level and its relationship with triglyceride and HbA1c in patients with coronary disease

Objective To compare the betatrophin levels in patients with coronary disease and controls so as to figure out its relationships with factors related to glucose and lipid metabolisms Methods Subjects were divided into 2 groups, i.e. coronary group (n = 107) and control group (n = 35). Based on the levels of glycosylated hemoglobin A1c (HbA1c), the coronary group was divided into normal-HbA1c and increased-HbA1c subgroups.  Other clinical indexes were examined by automatic analysis, which included triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine (Scr), uric acid (UA), high-sensitivity C-reactive protein (hsCRP), brain natriuretic peptide (BNP) and homocysteine (Hcy). Results Compared to the coronary group, plasma betatrophin level was lowered by 26.6% in the control group (P = 0.040). Betatrophin level of the normal-HbA1c subgroup decreased by 33.0% (P  = 0.001) compared with the control group, whereas betatrophin level in the increased-HbA1c subgroup increased by 22.6% compared to the normal-HbA1c subgroup (P = 0.020). Plasma betatrophin level was positively correlated with HbA1c level in the coronary group (r = 0.223, P = 0.021). In the coronary group, the male patients had significantly lower betatrophin levels than the female patients [(0.149 ± 0.068) vs (0.181 ± 0.078) ng/ml, P = 0.028]. Conclusions Betatrophin may be a new factor correlating to glucose and TG metabolisms in patients with coronary disease.